Quantiferon test for tuberculosis screening in sarcoidosis patients

References

• Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160: 736–55.
   PubMed Web of Science ®Google Scholar
• Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. II. Course and prognosis. Sarcoidosis 1990;7:113–8.
   PubMedGoogle Scholar
• Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J 2008;31:592–8.
   PubMed Web of Science ®Google Scholar
• Svendsen CB, Hummelshoj T, Munthe-Fog L, Milman N, Garred P, Laursen IA, . Ficolins and mannose-binding lectin in Danish patients with sarcoidosis. Respir Med 2008;102:1237–42.
   PubMed Web of Science ®Google Scholar
• Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis 1990;7:50–7.
   PubMedGoogle Scholar
• Gupta D, Agarwal R, Aggarwal AN, Jindal SK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J 2007;30:508–16.
   PubMed Web of Science ®Google Scholar
• Milman N. From mycobacteria to sarcoidosis—is the gate still open? Respiration 2006;73:14–5.
   PubMed Web of Science ®Google Scholar
• Svendsen CB, Milman N, Rasmussen EM, Thomsen VO, Andersen CB, Krogfelt KA. The continuing search for Mycobacterium tuberculosis involvement in sarcoidosis: a study on archival biopsy specimens. Clin Respir J 2011;5:99–104.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008;29:533–48.
   PubMed Web of Science ®Google Scholar
• Milman N, Graudal N, Jacobsen A, Baslund B. Adalimumab treatment in patients with sarcoidosis: an open clinical trial using FDG-PET. Eur Respir J 2010;36(Suppl 54):120S.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, . Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–104.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261–5.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372–9.
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620–7.
   PubMed Web of Science ®Google Scholar
• Chakravarty SD, Zhu G, Tsai MC, Mohan VP, Marino S, Kirschner DE, . Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916–26.
   PubMed Web of Science ®Google Scholar
• Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, . Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148–55.
   PubMed Web of Science ®Google Scholar
• Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol 2008;181:746–55.
   PubMed Web of Science ®Google Scholar
• Smith-Rohrberg D, Sharma SK. Tuberculin skin test among pulmonary sarcoidosis patients with and without tuberculosis: its utility for the screening of the two conditions in tuberculosis-endemic regions. Sarcoidosis Vasc Diffuse Lung Dis 2006;23:130–4.
   PubMed Web of Science ®Google Scholar
• Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, . Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876–84.
   PubMed Web of Science ®Google Scholar
• Hoffmann H, Loytved G, Bodmer T. [Interferon-gamma release assays in tuberculosis diagnostics]. Internist (Berl) 2007;48:497–6.
   PubMed Web of Science ®Google Scholar
• Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford) 2005;44:1205–6.
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003;52:15–8.
   PubMedGoogle Scholar
• Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther 2005;3:981–93.
   PubMedGoogle Scholar
• Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010;65:271–6.
   PubMed Web of Science ®Google Scholar
• Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, . Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37: 88–99.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Bianchi N, Margollicci M, Olivieri C, Luddi A, Coviello G, . Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Lab Invest 2008;68:479–83.
   PubMed Web of Science ®Google Scholar
• Norberg R. Studies in sarcoidosis. IV. Serum immunoglobulin levels. Acta Med Scand 1967;181:497–504.
   PubMedGoogle Scholar
• Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. BMJ 1961;2:1165–72.
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, . The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–206.
   PubMed Web of Science ®Google Scholar
• Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340–54.
   PubMed Web of Science ®Google Scholar
• Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177–84.
   PubMed Web of Science ®Google Scholar
• Inui N, Suda T, Chida K. Use of the QuantiFERON-TB Gold test in Japanese patients with sarcoidosis. Respir Med 2008;102:313–5.
   PubMed Web of Science ®Google Scholar
• Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, . Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011, doi: 10.1002/ibd.21605.
   PubMed Web of Science ®Google Scholar
• Lisby G, Milman N, Jacobsen GK. Search for Mycobacterium paratuberculosis DNA in tissue from patients with sarcoidosis by enzymatic gene amplification. APMIS 1993; 101:876–8.
   PubMed Web of Science ®Google Scholar
• Milman N, Andersen AB. Detection of antibodies in serum against M. tuberculosis using western blot technique. Comparison between sarcoidosis patients and healthy subjects. Sarcoidosis 1993;10:29–31.
   PubMedGoogle Scholar
• Milman N, Lisby G, Friis S, Kemp L. Prolonged culture for mycobacteria in mediastinal lymph nodes from patients with pulmonary sarcoidosis. A negative study. Sarcoidosis Vasc Diffuse Lung Dis 2004;21:25–8.
   PubMed Web of Science ®Google Scholar
• Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, . Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol 2007;150: 460–8.
   PubMed Web of Science ®Google Scholar
• Chen ES, Wahlstrom J, Song Z, Willett MH, Wiken M, Yung RC, . T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008;181:8784–96.
   PubMed Web of Science ®Google Scholar
• Moller DR. Potential etiologic agents in sarcoidosis. Proc Am Thorac Soc 2007;4:465–8.
   PubMedGoogle Scholar
• Song ZM, Marzilli L, Greenlee BM, Chen ES, Silver RE, Askin FB, . Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005;201:755–67.
   PubMed Web of Science ®Google Scholar
• Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, . Mycobacterium tuberculosis antigen 85A induces Th-1 immune responses in systemic sarcoidosis. J Clin Immunol 2007;27:445–54.
   PubMed Web of Science ®Google Scholar
• Dubaniewicz A, Trzonkowski P, Dubaniewicz-Wybieralska M, Dubaniewicz A, Singh M, Mysliwski A. Mycobacterial heat shock protein-induced blood T lymphocytes subsets and cytokine pattern: comparison of sarcoidosis with tuberculosis and healthy controls. Respirology 2007;12:346–54.
   PubMed Web of Science ®Google Scholar
• Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, . Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007;75:527–30.
   PubMed Web of Science ®Google Scholar